Clinical Commander

Back to dossier
cardio.acute-hf.elderly-frail.v1PRODUCTION
cardio.acute-hf.elderly-frail.v1

Acute HF — frail elderly (age ≥80, CFS ≥6)

cardiologyacuteadultgeriatric
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Age ≥80 + frailty (CFS ≥6 OR Fried ≥3) ADHF — functional outcomes (days at home, NYHA, 6MWT) prioritized over mortality; gentler doses; deprescribing focus; early GoC

Inputs
2
Actions
0
Advance rule
Set
Advance when

frailty staged + variant confirmed

Patient inputs (10)

Rockwood CFS ≥6 (moderately frail) drives gentler GDMT initiation, deprescribing thresholds, and goals-of-care discussion timing

Pre-admission NYHA + 6MWT (or get-up-and-go time) anchors target functional outcome; helps differentiate true acute decline vs end-stage trajectory

Polypharmacy >5 meds + Beers/STOPP-flagged drugs (anticholinergics, BZDs, NSAIDs, sliding-scale insulin) drive in-hospital deprescribing per STOPPFrail

Standing-supine BP gating GDMT initiation/up-titration; orthostasis (drop ≥20/10) → fall risk → start at 25% standard dose

Baseline + trend; tolerate ≤30% rise during decongestion but watch carefully — frail elderly slower to recover from AKI; eGFR for SGLT2i + ARNI dosing

Hyperkalemia risk with MRA + ARNI in eGFR <45 frail elderly; lower starting doses + closer monitoring

Baseline cognition (Mini-Cog or 4AT) anchors delirium detection during admission — BB + diuretic-induced delirium common in frail elderly

Early GoC conversation (within 48h) — frailty + ADHF carries 1-yr mortality 25-50% per Khan 2020; aligns aggressiveness with patient values

Age ≥80 defines variant; biological vs chronological age via frailty stratifies risk

NT-proBNP elevated baseline in elderly + renal — use trend (>30% drop) rather than absolute

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationalseverefrail_elderly_with_delirium_during_adhf_admission
    CAM-positive delirium during ADHF treatment in age ≥80 + CFS ≥6 — often BB, opioid, BZD, or anticholinergic-induced
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefrail_elderly_with_fall_on_diuretic_or_after_gdmt_initiation
    Fall during admission or within 1 month of new diuretic dose increase or GDMT initiation in age ≥80 + CFS ≥6
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefrail_elderly_with_aki_from_over_diuresis
    Cr rise >50% from baseline OR Cr ≥2.0 in age ≥80 + CFS ≥6 within 24-72h of IV loop diuretic
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefrail_elderly_with_polypharmacy_adverse_event
    Adverse drug event identified as STOPPFrail-flagged class — BZD-related sedation, anticholinergic delirium, sliding-scale insulin hypoglycemia, NSAID nephrotoxicity
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Frail-elderly ADHF — gentler decongestion + 25% GDMT + deprescribing per STOPPFrail (ACC/AHA 2022 §11; Khan 2020; CSANZ HFSA 2024)
axis: frail_elderly_adhf_gentler_phenotype
Selected axis "Frail-elderly ADHF — gentler decongestion + 25% GDMT + deprescribing per STOPPFrail (ACC/AHA 2022 §11; Khan 2020; CSANZ HFSA 2024)" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    IV 1-1.5× home dose (NOT 2-2.5×); if naïve start 20-40 mg IV (NOT 80 mg); reassess UOP at 4h (NOT 2h) • IV • q8-12h titrate
    triggers: frail_elderly_adhf_with_volume_overload
    DOSE PMID 21366472 — high-dose IV loop NOT validated in frail elderly; gentler dosing avoids AKI + electrolyte disturbances + falls + delirium; tolerate slower decongestion to preserve renal function
    rxcui 4603
  • carvedilol
    first line
    beta_blocker
    1.5625 mg PO BID (1/2 of standard 3.125 starter); titrate q4 weeks NOT q2 weeks; target may be 6.25 BID NOT 25 BID • PO • BID
    triggers: hfref_in_frail_elderly_post_decongestion
    SENIORS PMID 15642706 — BB benefit in elderly preserved but tolerability requires lower starting + slower titration; CSANZ HFSA 2024 frail HF position; STRONG-HF subgroup PMID 36356631
    rxcui 20352
  • sacubitril-valsartan
    first line
    arni
    12/13 mg PO BID (1/2 of standard 24/26 starter); titrate q4 wk if SBP ≥110 + Cr stable + K <5.0 • PO • BID
    triggers: hfref_in_frail_elderly_post_decongestion_sbp_above_110
    PIONEER-HF PMID 30403955 elderly subgroup — ARNI benefit preserved; lower starting dose mitigates orthostatic hypotension risk; HOLD if symptomatic orthostasis
    rxcui 1656328
  • empagliflozin
    first line
    SGLT2_inhibitor
    10 mg PO daily — full standard dose (NO renal-elderly dose adjustment unless eGFR <20) • PO • daily
    triggers: hfref_or_hfpef_in_frail_elderly_egfr_above_20
    EMPULSE PMID 35347356 + DELIVER PMID 36027564 elderly subgroup — well-tolerated; preserved benefit with same-dose; monitor for euvolemia (mild diuretic effect)
    rxcui 1545653
  • spironolactone
    first line
    mra
    12.5 mg PO every other day (NOT daily 25 mg) if eGFR 30-45; 12.5 mg daily if eGFR ≥45; HOLD if eGFR <30 • PO • every other day or daily
    triggers: hfref_in_frail_elderly_egfr_above_30_k_below_5
    EMPHASIS-HF elderly subgroup — benefit preserved but hyperK risk doubled; ultra-low starter + every-other-day dosing if borderline renal; check K + Cr at week 1 then q2 wk
    rxcui 9997
  • midodrine
    comorbidity specific
    alpha1_agonist
    2.5 mg PO TID titrate to 5-10 mg TID; last dose by 4 PM (avoid supine HTN at night) • PO • TID
    triggers: symptomatic_orthostasis_limiting_gdmt_titration
    Permits GDMT up-titration in patients with orthostasis-limited regimen; do NOT use if supine HTN; common useful adjunct in frail HF per CSANZ HFSA 2024
    rxcui 6963
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    2.5 mg PO BID (dose-reduction criteria: age ≥80 + Cr ≥1.5 + weight ≤60 kg = 2 of 3); standard 5 mg BID if not meeting reduction criteria • PO • BID
    triggers: af_with_chads_vasc_above_2, lv_thrombus_post_mi
    ARISTOTLE elderly subgroup — apixaban preferred over warfarin in frail elderly (lower bleeding); auto dose-reduction in elderly per label
    rxcui 1364430

outpatient playbook — drug actions (2)

  1. 1. maintain GDMT at max-tolerated (often 25-50% standard)
    rxcui 593411
    ARNI + BB + MRA + SGLT2i at max tolerated • PO • as scheduled
    trigger: HFrEF + tolerated
    CSANZ HFSA 2024 — sub-target doses acceptable in frail HF if functional benefit; do not chase target if causing orthostasis or AKI
  2. 2. ongoing deprescribing audit
    review STOPPFrail + Beers q3 mo • PO • audit
    trigger: progressive frailty or polypharmacy creep
    Lavan 2017 STOPPFrail; Beers 2023

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Age ≥80 + ADHF presentation → frail-HF screen + geriatric-aware management; Clinical Frailty Scale (Rockwood) ≥6 (moderately frail) at baseline → frail HF pathway; Fried frailty phenotype ≥3 of 5 (weight loss, exhaustion, weakness, slow gait, low activity) → frail HF pathway.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — frail elderly (age ≥80, CFS ≥6)** (cardio.acute-hf.elderly-frail.v1).
Scope: Age ≥80 + frailty (CFS ≥6 OR Fried ≥3) ADHF — functional outcomes (days at home, NYHA, 6MWT) prioritized over mortality; gentler doses; deprescribing focus; early GoC

No severity triggers fired against current inputs.

Plan

Regimen axis: **Frail-elderly ADHF — gentler decongestion + 25% GDMT + deprescribing per STOPPFrail (ACC/AHA 2022 §11; Khan 2020; CSANZ HFSA 2024)**.
1. furosemide IV 1-1.5× home dose (NOT 2-2.5×); if naïve start 20-40 mg IV (NOT 80 mg); reassess UOP at 4h (NOT 2h) IV q8-12h titrate (loop_diuretic, first line) — DOSE PMID 21366472 — high-dose IV loop NOT validated in frail elderly; gentler dosing avoids AKI + electrolyte disturbances + falls + delirium; tolerate slower decongestion to preserve renal function
2. carvedilol 1.5625 mg PO BID (1/2 of standard 3.125 starter); titrate q4 weeks NOT q2 weeks; target may be 6.25 BID NOT 25 BID PO BID (beta_blocker, first line) — SENIORS PMID 15642706 — BB benefit in elderly preserved but tolerability requires lower starting + slower titration; CSANZ HFSA 2024 frail HF position; STRONG-HF subgroup PMID 36356631
3. sacubitril-valsartan 12/13 mg PO BID (1/2 of standard 24/26 starter); titrate q4 wk if SBP ≥110 + Cr stable + K <5.0 PO BID (arni, first line) — PIONEER-HF PMID 30403955 elderly subgroup — ARNI benefit preserved; lower starting dose mitigates orthostatic hypotension risk; HOLD if symptomatic orthostasis
4. empagliflozin 10 mg PO daily — full standard dose (NO renal-elderly dose adjustment unless eGFR <20) PO daily (SGLT2_inhibitor, first line) — EMPULSE PMID 35347356 + DELIVER PMID 36027564 elderly subgroup — well-tolerated; preserved benefit with same-dose; monitor for euvolemia (mild diuretic effect)
5. spironolactone 12.5 mg PO every other day (NOT daily 25 mg) if eGFR 30-45; 12.5 mg daily if eGFR ≥45; HOLD if eGFR <30 PO every other day or daily (mra, first line) — EMPHASIS-HF elderly subgroup — benefit preserved but hyperK risk doubled; ultra-low starter + every-other-day dosing if borderline renal; check K + Cr at week 1 then q2 wk
6. midodrine 2.5 mg PO TID titrate to 5-10 mg TID; last dose by 4 PM (avoid supine HTN at night) PO TID (alpha1_agonist, comorbidity specific) — Permits GDMT up-titration in patients with orthostasis-limited regimen; do NOT use if supine HTN; common useful adjunct in frail HF per CSANZ HFSA 2024
7. apixaban 2.5 mg PO BID (dose-reduction criteria: age ≥80 + Cr ≥1.5 + weight ≤60 kg = 2 of 3); standard 5 mg BID if not meeting reduction criteria PO BID (doac_factor_xa_direct, comorbidity specific) — ARISTOTLE elderly subgroup — apixaban preferred over warfarin in frail elderly (lower bleeding); auto dose-reduction in elderly per label

Setting playbook (outpatient) — Long-term frail-HF surveillance; functional outcome focus (days at home, NYHA, 6MWT); ongoing deprescribing; advance directives + palliative care integration; ICD/CRT eligibility usually NOT recommended in CFS ≥6
8. maintain GDMT at max-tolerated (often 25-50% standard) ARNI + BB + MRA + SGLT2i at max tolerated PO as scheduled — HFrEF + tolerated (CSANZ HFSA 2024 — sub-target doses acceptable in frail HF if functional benefit; do not chase target if causing orthostasis or AKI)
9. ongoing deprescribing audit review STOPPFrail + Beers q3 mo PO audit — progressive frailty or polypharmacy creep (Lavan 2017 STOPPFrail; Beers 2023)

Non-pharmacologic actions:
- Palliative care co-management if CFS ≥7 or NYHA IV
- POLST/MOLST in place
- Hospice referral if life expectancy <6 mo per gold-standards-framework

AVOID / contraindication checks:
- Avoid_high_dose_iv_loop_2_5x_in_frail_elderly (DOSE elderly subgroup; AKI + fall + delirium risk; use 1 1.5× home dose)
- Avoid_standard_starting_dose_carvedilol_in_cfs_ge_6 (start 1.5625 mg BID; STOPPFrail; CSANZ HFSA 2024)
- Avoid_standard_starting_dose_arni_in_cfs_ge_6 (start 12/13 BID; orthostasis risk)
- Avoid_daily_mra_if_egfr_30_45_in_elderly (every other day starter; hyperK risk doubled)
- Deprescribe_statin_in_nyha_iv_with_life_expectancy_below_1_yr (CESAR/SAVE AHF; STOPPFrail)
- Deprescribe_sliding_scale_insulin_in_frail_elderly (Beers 2023; hypoglycemia risk; switch to basal only)
- Deprescribe_bzd_anticholinergic_in_frail_elderly (Beers 2023 STOPP/START; falls + delirium)
- Deprescribe_nsaid_in_hf_or_ckd (KDIGO 2024; nephrotoxin)
- Hold_acei_arb_arni_if_orthostasis_or_aki (ACC/AHA 2022 §11.4)
- Apixaban_dose_reduce_if_age_80_cr_1.5_weight_60_two_of_three (drug label)

Monitoring

Regimen monitoring:
- daily supine and standing bp (orthostasis screen for fall risk)
- daily weight and strict io (decongestion endpoint with frail-elderly-tolerable cadence)
- BMP q12h during diuresis (K + Cr + Mg trend; tolerate ≤30% Cr rise but lower threshold than younger adults)
- CAM ICU q shift for delirium (BB + diuretic + opioid common precipitants)
- morse or johns hopkins fall risk q shift (orthostasis + diuresis + new BB → fall cluster)
- STOPPFrail review q 24h (ongoing deprescribing audit during admission)
- medication reconciliation at every transition (admission, transfer, discharge)
- 6MWT or get up go pre discharge (functional outcome target)

Setting (outpatient) monitoring:
- Quarterly clinic + annual echo
- Quarterly STOPPFrail audit

Follow-up plan: STRONG-HF SLOW cadence (q4 wk not q2 wk titration in CFS ≥6 per Mebazaa subgroup); 1-wk PCP visit + 2-wk HF clinic (in-home if homebound); home-health PT for fall prevention; medication reconciliation at every visit; advance directives finalized
- Close-out criterion: home-based follow-up + advance directives + AOM/Tele-HF arranged

Monitoring phase: Daily weight + supine/standing BP, hourly UOP, BMP q12h during diuresis, CAM-ICU q shift for delirium, fall risk score q shift, daily medication review for STOPP triggers

Disposition

Current setting: outpatient — Long-term frail-HF surveillance; functional outcome focus (days at home, NYHA, 6MWT); ongoing deprescribing; advance directives + palliative care integration; ICD/CRT eligibility usually NOT recommended in CFS ≥6

Disposition criteria:
- Long-term continuation; transition to hospice when functional decline + NYHA IV + frequent admissions

Escalation triggers (move to higher acuity):
- Recurrent ADHF → revisit deprescribing + GoC
- Functional decline (NYHA worsening, 6MWT drop >50m) → palliative + GoC
- New delirium episodes → med review

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] CAM-positive delirium during ADHF treatment in age ≥80 + CFS ≥6 — often BB, opioid, BZD, or anticholinergic-induced
- [SEVERE] Fall during admission or within 1 month of new diuretic dose increase or GDMT initiation in age ≥80 + CFS ≥6
- [SEVERE] Cr rise >50% from baseline OR Cr ≥2.0 in age ≥80 + CFS ≥6 within 24-72h of IV loop diuretic

Citations

- 2022 ACC/AHA HF §11 geriatrics + 2024 CSANZ HFSA frail-HF position + STOPPFrail (Lavan 2017) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 38264914) [PMID:38264914](https://pubmed.ncbi.nlm.nih.gov/38264914/)
- Cited evidence (PMID 33163319) [PMID:33163319](https://pubmed.ncbi.nlm.nih.gov/33163319/)
- Cited evidence (PMID 15642706) [PMID:15642706](https://pubmed.ncbi.nlm.nih.gov/15642706/)
- Cited evidence (PMID 30403955) [PMID:30403955](https://pubmed.ncbi.nlm.nih.gov/30403955/)

Last reconciled with current guidelines: 2026-05-15.
References